Katalog der Deutschen Nationalbibliothek

Neuigkeiten Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00
 
Neuigkeiten Dienstag 9. Dezember 2025: Die Lesesäle der Deutschen Nationalbibliothek in Leipzig öffnen wegen einer Personalversammlung erst ab 13 Uhr. // Tuesday 9 December 2025: The reading rooms of the German National Library in Leipzig will open at 13:00 due to a staff assembly.
 
 
 


Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

81 - 90 von 117
<< < > >>


Artikel 81 Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim
Enthalten in Annals of hematology Bd. 103, 8.1.2024, Nr. 3, date:3.2024: 947-956 		Online Ressource
Artikel 82 Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
Enthalten in Indian journal of gastroenterology Bd. 41, 15.11.2022, Nr. 5, date:10.2022: 446-455 		Online Ressource
Artikel 83 Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
Enthalten in BioDrugs Bd. 38, 22.11.2023, Nr. 1, date:1.2024: 121-131 		Online Ressource
Artikel 84 Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
Enthalten in BioDrugs Bd. 34, 23.9.2020, Nr. 5, date:10.2020: 681-694 		Online Ressource
Artikel 85 Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review
Enthalten in BioDrugs Bd. 32, 22.5.2018, Nr. 3, date:6.2018: 193-199 		Online Ressource
Artikel 86 Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study
Enthalten in BioDrugs Bd. 35, 16.10.2021, Nr. 6, date:11.2021: 735-748 		Online Ressource
Artikel 87 Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin
Enthalten in Diabetes therapy Bd. 13, 1.6.2022, Nr. 7, date:7.2022: 1299-1310 		Online Ressource
Artikel 88 Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
Enthalten in Diabetes therapy Bd. 12, 11.1.2021, Nr. 2, date:2.2021: 557-568 		Online Ressource
Artikel 89 Erythropoietin-induced Treatment Costs in Patients Suffering from Renal Anemia – A Comparison between Biosimilar and Originator Drugs
Enthalten in Das Gesundheitswesen Bd. 76, 2014, Nr. 11: e79-e84 		Online Ressource
Artikel 90 Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial
Enthalten in Scientific reports Bd. 14, 22.10.2024, Nr. 1, date:12.2024: 1-12 		Online Ressource


81 - 90 von 117
<< < > >>




Materialarten

Alle Materialarten > Artikel (117)

Standorte

Alle Standorte > Leipzig (117)

Aktionen

Aktionen


E-Mail-IconAdministration